Product and process for mucus viscosity normalization

Inventors

Heifetz, Peter B.

Assignees

ORPRO THERAPEUTICS Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12390511-B2

Patent

Publication Date

2025-08-19

Expiration Date


Abstract

Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.

Core Innovation

The disclosed invention provides compositions and methods for treating respiratory conditions by administering a composition containing a protein or peptide with a thioredoxin monocysteinic active site in a reduced state. The thioredoxin monocysteinic active site comprises an amino acid sequence selected from C-X-X-S (SEQ ID NO: 24), X-C-G-P-X-X (SEQ ID NO: 21), W-C-G-P-X-K (SEQ ID NO: 23), X-C-X-X-S-X (SEQ ID NO: 25), X-C-G-P-S-X (SEQ ID NO: 26), and W-C-G-P-S-K (SEQ ID NO: 27), and the X residues are any amino acid residue other than cysteine.

The problem addressed is abnormal mucus or sputum viscosity and cohesiveness, including abnormal mucins associated with respiratory disease. The disclosed approach normalizes abnormally viscous or cohesive mucus/sputum by reducing mucin disulfide bonds to increase free thiols, increase liquid fraction, and decrease viscoelasticity, thereby improving properties relevant to respiratory function as described in the document.

In addition to respiratory treatment, the document includes non-respiratory mucus-associated conditions. The disclosure further supports delivery routes and formulations including nasal, intratracheal/bronchial/direct lung instillation, inhaled delivery, oral delivery, aerosol and nebulizer formulations, including vibrating-mesh nebulizers.

Claims Coverage

The partial set identifies two independent claims, each centering on administering a thioredoxin monocysteinic active site protein or peptide in a reduced state. Both independent claims define the inventive composition by sequence motifs for the monocysteinic active site and specify patient treatment, with one claim focusing on a respiratory condition and the other focusing on selected lung diseases and formulation categories.

Reduced-state thioredoxin monocysteinic active site for respiratory treatment

Administering a composition containing a protein or peptide with a thioredoxin monocysteinic active site in a reduced state to the respiratory tract of the patient, wherein the thioredoxin monocysteinic active site comprises an amino acid sequence selected from C-X-X-S (SEQ ID NO: 24), X-C-G-P-X-X (SEQ ID NO: 21), W-C-G-P-X-K (SEQ ID NO: 23), X-C-X-X-S-X (SEQ ID NO: 25), X-C-G-P-S-X (SEQ ID NO: 26), and W-C-G-P-S-K (SEQ ID NO: 27), and the X residues are any amino acid residue other than cysteine.

Reduced-state thioredoxin monocysteinic active site composition for selected lung diseases

Treating a disease selected from cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and asthma by administering to the patient a pharmaceutical composition containing a protein or peptide with a thioredoxin monocysteinic active site in a reduced state, where the composition is formulated for oral administration, topical administration, or aerosol administration to the lung, and the thioredoxin monocysteinic active site comprises an amino acid sequence selected from C-X-X-S (SEQ ID NO: 24), X-C-G-P-X-X (SEQ ID NO: 21), W-C-G-P-X-K (SEQ ID NO: 23), X-C-X-X-S-X (SEQ ID NO: 25), X-C-G-P-S-X (SEQ ID NO: 26), and W-C-G-P-S-K (SEQ ID NO: 27), and the X residues are any amino acid residue other than cysteine.

Across the two independent claims, the core claimed inventive concept is the administration of a pharmaceutical composition containing a thioredoxin monocysteinic active site protein or peptide in a reduced state, with the active-site sequence constrained to the provided SEQ ID motif group and non-cysteine X residues. The claims differ in scope of the target disease set and in formulation categories, with one claim directed to a respiratory condition and the other directed to specific lung diseases and oral, topical, or aerosol-to-lung formulations.

Stated Advantages

Normalizes abnormally viscous or cohesive mucus or sputum by reducing mucin disulfides, increasing free thiols, increasing liquid fraction, and decreasing viscoelasticity.

Improves properties relevant to respiratory conditions by reducing disulfide-linked mucin cohesiveness.

Documented Applications

Treatment of cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and asthma by administering a reduced-state thioredoxin monocysteinic active site protein or peptide composition to the respiratory tract or as formulated for oral, topical, or aerosol delivery to the lung.

Reduction or normalization of abnormally viscous or cohesive mucus or sputum, including liquefaction effects described via increased liquid fraction and decreased viscoelasticity.

Non-respiratory mucus-associated condition treatment, including coccidiosis.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.